SB-228357
Chemical compound
From Wikipedia, the free encyclopedia
SB-228357 is a drug which acts as a selective antagonist of the serotonin 5-HT2B and 5-HT2C receptors.[1][2]
| |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C22H17F4N3O2 |
| Molar mass | 431.391 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It has antidepressant and anxiolytic effects in animal models[1][2] and inhibits 5-HT2B mediated proliferation of cardiac fibroblasts.[3] It has also been found to reverse meta-chlorophenylpiperazine (mCPP)-induced hypolocomotion[2] and to attenuate haloperidol-induced catalepsy.[1]
The drug was under development by GlaxoSmithKline for the treatment of major depressive disorder and anxiety disorders.[4] It reached the preclinical research phase of development.[4] However, development of the drug was discontinued.[4]
